Deprenyl / Selegiline sustains the availability of dopamine in our brains as we age which helps us maintain youthful cognitive functions. Deprenyl acts as a nerve and brain cell protector, this powerful ‘smart drug’ or nootropic is approved for use in the treatment of Parkinson’s but is used ‘off label’ for many other conditions including Alzheimer’s disease (AD), depression and multiple sclerosis.
Dopamine plays key roles in numerous cognitive functions but levels decrease with age especially after the age of 40. Preserving the quantity of available dopamine reduces cell deterioration in key parts of the brain where dopamine is transmitted – prolonging lucidity and extending life expectancy potential.
The graph opposite highlights the loss of dopamine with age, on average 13% per decade past the age of 40 for the average person, but far greater for those suffering from Parkinson’s disease.
Professor Knoll a world leading authority on Deprenyl noted that the nigrostriatal tract, the tiny Dopamine serving nerve cluster in the basal ganglia typically dies off at an average rate of 13% per decade starting at around age 45.
Professor Knoll suggests by using Deprenyl from around aged 40 when the decline begins to become rapid, the nigostriatal neuron death rate could be lowered and life expectancy could therefore be increased in this respect. Couple this with the increased effectiveness of brain function in later life and a direct positive effect on quality of life is attained.
Since the manufacture of Cyprenil was discontinued we are one of the few stockists in the world that still offer a liquid Deprenyl, the liquid version is perfect for antiaging programs as it allows the use of very small doses regularly in order to help maintain healthy dopamine levels which improves cognitive function and helps to maintain function at a better level for much longer.
The prime advantages of the liquid deprenyl are twofold:
A daily dose of Jumex Deprenyl tablets is 10 mg either in the morning or divided into two doses of 5 mg at breakfast and lunchtime.
Please note that both the Deprenyl products we stock Dep Pro Deprenyl Liquid and Jumex Selegiline tablets are the more thoroughly researched HCL version, not Deprenyl Citrate.
Deprenyl / Selegiline like all nootropics is defined as a drug that is neuroprotective, non-toxic, and possess few side effects.
Deprenyl, by protecting dopamine levels in the brain is a cognitive enhancing smart drug that works to improve brain function, facilitate faster cognitive actions and improve concentration. If you are looking for Deprenyl, buy it from a reputable stockist such as Antiaging-Systems.
Disclaimer: Please note that only your own physician can determine your precise needs, but in order to give you some information these answers are based upon the ‘average person’ and clinical / published results.
If selegiline (deprenyl) is used in combination for old fashioned non-selective MAO inhibitors, could it theoretically prevent these medications from causing the cheese effect?
We understand that whilst there is evidence that deprenyl can prevent tyramine from entering noradrenaline using cells, we cannot find the degree of its effectiveness, as it would be unlikely to block all the action of tyramine, and even then there would be a wide variance of criteria, including dosages that would influence the outcome.
As such, whilst its titration may benefit from reducing or eliminating a cheese effect for a patient, there is no clear evidence that deprenyl could be used for such a purpose. Therefore we would not recommend deprenyl being used in this way.
However, what is clear is that deprenyl does not cause the ‘cheese effect’ by itself.
Can deprenyl be used with other MAO inhibitors?
It is not recommended to concurrently use deprenyl with other MAO inhibitors.
I get random drug tests and I was told that deprenyl can test positive for amphetamine metabolites, is this true?
In previous years this would not have been the case, but there have been some recent changes to some drug testing that could cause problems. In the past the amphetamine tests only looked for l-amphetamine, the active form that deprenyl does not contain. However, some of the newer tests also look for the d-amphetamine which deprenyl does contain, whilst this form does not induce amphetamine effects some of these new drug tests would create a ‘false positive’ effect with deprenyl users.
If you are regularly being drug tested you should be aware of this possibility and ensure that you list deprenyl / seligiline onto your medicine list. Alternatively a ‘wash out’ of deprenyl can be entertained prior to a test, but to ensure zero count (and obviously dependent upon the dose) this could take up to 3-weeks.
From what source is the selegiline (deprenyl) derived (organic-plant or chemical)?
Selegiline is derived via a pharmaceutical process from plant materials; I believe the original material is the Chinese herb ephedra.
I am taking 9mg of Deprenyl a day and experiencing stomach cramps, nausea and diarrhea, is the Deprenyl causing this?
Yes it could be that this relatively high dose of deprenyl is causing some of the side effects you are experiencing. Whilst we are aware that some manufacturers recommend dosages in excess of 5 mg daily based on age, we are of the opinion that unless some forms of dementia, such as Parkinson’s is present, that there is no need to exceed an amount of 5 mg daily.
Most preventative medicine dosages are 1 to 3 mg daily, and we strongly recommend that dosages in excess of 5 mg daily are built up to gradually, so for example adding an additional 1 mg each week, providing no side effects are noted etc. It may well be possible that you can take the full 9 mg as recommended by the manufacturer, but that for now you should reduce your dosage to say 5 mg (or lower if necessary) and only attempt to increase this dosage as gradually as possible.
We also recommend taking occasional breaks from deprenyl use, some people prefer 1-week a month; many take deprenyl in the weekdays and none at the weekend.
Would you be so kind as to help me understand why it is that deprenyl in my case fails to raise my sex drive? Could it be that if used alone it won't raise dopamine? Is it mandatory to use B6 + DLPA along with it for one DA to be raised?
Deprenyl usually takes about 3-weeks to get to a level whereby it is enhancing dopamine levels, of course much may also depend on the dosages you are taking, you didn’t mention those or your bodyweight which can also be a factor, however we don’t normally recommend more than 5 mg per day.
We would recommend that you read biochemist James South article at: here in which he states the following:
In 1991 H. Sabelli reported successful results treating 6 of 10 drug-resistant major depressive disorder patients. (9) Sabelli used 5 mg DPR daily, 100 mg vitamin B6 daily, and 1-3 grams phenylalanine twice daily as treatment. 6 of 10 patients viewed their depressive episodes terminated within 2-3 days! Global Assessment Scale scores confirmed the patients’ subjective experiences. Vitamin B6 activates the enzyme that converts phenylalanine to PEA, so the combination of low-dose DPR, B6, and phenylalanine is a bio-logical way to enhance both PEA and catecholamine brain function, and thus to diminish depression.
Therefore the addition of 100 mg vitamin B6 and 1-3 grams phenylalanine may be beneficial for libido also, and although the above study was for depression, the fact that deprenyl enhances PEA more than it enhances dopamine may be a clue to its effectiveness, as the actual process of enhancing libido is not yet fully understood.
We have many more articles that contain references to deprenyl in them, a listing can be seen at: http://www.antiaging-systems.com/50-deprenyl
It is not mandatory to add B6 and DLPA to deprenyl to raise dopamine levels, but that methylation (the conversion of one chemical to another in the body) varies widely from person to person and that some people will need to ensure adequate nutritional intake in the form of vitamins, enzymes and similar to have effective methylation.
Parkinson and Alzheimer's disease patients are often treated with very high doses of 20mg daily (usually along with other drugs). Selegiline antiaging doses (dependant on age and condition) are more likely to be 2.5mg to 5mg once, twice or three times a week, or 1mg to 3mg per day, with regular breaks. Deprenyl liquid can be titrated precisely for antiaging purposes, as each ml drop in the bottle is equivalent to 1mg deprenyl citrate and regular doses are considered to be 1mg to 3mg daily. Ward Dean MD, recommends reducing deprenyl doses after several months to lower levels and taking occasional sabbaticals.
Deprenyl effects are similar to those experienced with other nootropics like cerestabon or pyritinol effects. Possible gastrointestinal symptoms, such as nausea, heartburn, upset stomach, etc. Some studies have found side effects such as irritability, hyper-excitability, psychomotor agitation and insomnia. These effects are probably due to Deprenyl catecholamine-enhancing effect, over-activating DNA neural systems at the expense of calming / sleep-inducing serotonergic systems, so taking magnesium and Tryptophan or 5HTP may suffice to counter these ‘psychic’ effects.
Dopamine is a naturally occurring chemical in our brains that affects all sorts of essential mental facilities like concentration, memory and alertness. As we age, the levels of dopamine that our body produces, drops. This means that as time goes by, the ability of our brains to function at optimum, more youthful levels, deteriorates.
Deprenyl boosts dopamine levels and protects brain cells by working to improve brain function – a reason why it’s a treatment alzheimer disease sufferers turn to. By protecting the brain cells and increasing dopamine, deprenyl can keep our minds sharper for longer.
Ingredients: Selegiline, water, glycerin, potassium sorbate, lemon extract, citric acid and sodium citrate.
Dosing: 1 drop = 1 mg selegiline HCL
Lactose, cornstarch, polyvinyl pyrrolidone, monohydric citric acid, magnesium stearate.
Selegiline is often given as an adjunct to levodopa therapy and many of the adverse effects reported can be attributed to enhanced levodopa activity- dosage of levodopa may have to be reduced. Adverse effects have included hypertension, nausea, confusion, psychosis, hallucinations, and increased dyskinesias. Unlike non-selective monoamine oxidase inhibitors such as phenelzine, selegiline is reported not to interact with tyramine in food at usual doses, but see below under Interactions.
Although selegiline is less likely than non-selective monoamine oxidase inhibitors to interact with tyramine in food, like other monoamine oxidase inhibitors it can produce life-threatening reactions when given with pethidine. Zornberg GL, et al. severe adverse interaction between pethidine and selegiline. Lancet 1991- 337: 246. Correction. ibid.- 440.
Selegiline hydrochloride is a selective inhibitor of monoamine oxidase type B, an enzyme involved in the metabolic degradation of dopamine in the brain. It enhances the effects of levodopa and is used in Parkinson's disease as an adjunct to levodopa therapy, usually when fluctuations in mobility have become a problem. It is administered in a daily dose of 10 mg, either as a single dose in the morning or in 2 divided doses of 5 mg at breakfast and lunchtime.
Addition of selegiline to levodopa therapy may enable the dosage of levodopa to be reduced by an average of 30%. Selegiline may also be given alone in early Parkinson's disease in an attempt to slow disease progression (see under Parkinsonism, below). A dose of 10 mg of the hydrochloride daily has been suggested for this purpose.
Double-blind studies (1,2) indicate that selegiline may produce beneficial effect in-patients with Alzheimer's disease but it has been suggested that improvements in mood and cognitive function may be due to a reduction in tension and depression. (3) 1. Piccinin GL, et al. neuropsychological effects of L-deprenyl in Alzheimer's type dementia. Clin Neuropharmacol 1990- 13: 147-63. 2. Mangoni A, et al. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur Neurol 1991- 31: 100-107. 3. Anonymous. Drugs for Alzheimer's disease. Drug Ther Bull 1990- 28: 42-4.
Several studies have suggested that like non-selective monoamine oxidase inhibitors such as phenelzine, selegiline may be of some benefit in depression. Mendlewicz and Youdim reported a marked improvement in 14 patients with unipolar or bipolar depression who received selegiline hydrochloride 5 mg three times daily for 40 days compared with 13 patients given placebo. (1) Similarly, Birkmayer et al. reported benefit in an uncontrolled study in 102 outpatients and 53 inpatients with unipolar depression who received selegiline hydrochloride 5 to 10 mg daily in association with phenylalanine 250 mg daily- about 70% of these patients, in whom conventional antidepressants were not effective, were reported as having complete remission. (2) The benefit was not thought to be due to the amphetamine metabolites of selegiline. Benefit has also been reported in-patients with atypical depression who received selegiline hydrochloride in doses of 10 to 40 mg daily. (3) At high doses the specificity of inhibition is reported to be lost and restriction of tyramine in the diet becomes necessary as with more conventional monoamine oxidase inhibitors- in this study there was little evidence of such a loss of specificity. 1. Mendlewicz J, Youdim MBH. L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double-blind evaluation. Br J Psychiatry 1983- 142: 508-11 2. Birkmayer W, et al. L-Deprenyl plus L-phenylalanine in the treatment of depression. J Neural Transm 1984- 59: 81-7. 3. Quitkin FM, et al. l-Deprenyl in atypical depressives. Arch Gen Psychiatry 1984- 41: 777-81.
Early attempts to prolong the actions of dopamine in the brain by administration of monoamine oxidase inhibitors were unsuccessful because of intolerable side effects and the risk of potentially catastrophic hypertension. However, the discovery that monoamine oxidase (MAO) exists in at least 2 forms, A and B, and the realization that dopamine in the brain is metabolized predominantly by MAO-B led to the identification of selegiline, which could delay oxidative diminution of dopamine in the brain without provoking a `cheese-reaction'. (1) When given to patients experiencing fluctuations in levodopa's effect due to `wearing-off' or `end-of-dose' effects selegiline ameliorates the fluctuations in about 50 to 70% of patients, and permits a reduction in levodopa dosage of up to about 30%. (2,3) However the benefit is usually modest, and declines after 6 to 12 months in most patients with complete loss of benefit usually in 12 to 24 months. (2) More severe fluctuations in mobility associated with the `on-off' effect in advanced Parkinsonism are unlikely to respond to adjuvant selegiline. (3) More recently much interest and controversy has surrounded the possibility that selegiline given in early Parkinson's disease may retard disease progression. Several uncontrolled studies had reported that long-term administration of selegiline with levodopa prolonged the period of responsiveness to the latter and resulted in increased life expectancy of parkinsonian patients. (4,5) Furthermore, a theoretical basis for benefit exists in the model of Parkinsonism caused by methylphenyltetrahydropyridine (MPTP) which relies on conversion by monoamine oxidase type B to the active methylphenylpyridinium (MPP (+)) radical to produce damage to the striatum. (3,6) More recently, controlled studies by Tetrud and Langston (in 54 patients) (7) and by the Parkinson Study Group (the DATATOP study, involving 800 patients) (8) have shown a significant prolongation in the time to reach a level of disability requiring commencement of levodopa therapy. Although some critics have suggested that selegiline is simply providing symptomatic relief in disease which continues to progress (9-11) the promising preliminary results have been suggested by others to justify the prescription of selegiline 10 mg daily to patients, especially younger ones, in the early stages of Parkinson's disease, in the hope of impeding progression. (12)
1. Anonymous. Deprenyl in Parkinson's disease. Lancet 1982- ii: 695-6. 2. Anonymous. Pergolide and selegiline for Parkinson's disease. Med Lett Drugs Ther 1989- 31: 81-3. Golbe LI, et al. Selegiline and Parkinson's disease: protective and symptomatic considerations. Drugs 1990- 39: 646-51. 4. Birkmayer W, et al. (-)-Deprenyl leads to prolongation of L-Dopa efficacy in Parkinson's disease. Mod Probl Pharmacopsychiatry 1983- 19: 170-6. 5 Birkmayer W, et al. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a long term study. J Neural Transm 1985- 64: 113-27. 6. Steventon G, et al. Monoamine oxidase B and Parkinson's disease. Lancet 1990- 335: 180. 7.
The above information is the translation of the manufacturer's insert. It is provided under the supplying company's terms and conditions and should not replace the advice of your personal physician.
Each tablet contains: Main ingredient: 5 mg selegiline hydrochloride (L-deprenyl). Other ingredients: lactose, cornstarch, povidone, monohydrate citric acid, magnesium stearate.
Anti-Parkinson agent and monoamine oxidase type-B inhibitor.
Parkinson’s disease and its symptoms: When taken as a single treatment in the early stages of the disease (“early onset” Parkinson’s disease), Seligiline clinically improves the patient’s disability and delays the development of the disease, significantly postponing the need to begin levodopa treatment.
Hypersensitivity to the product’s ingredients: Seligiline should not be used to treat extrapyramidal syndromes not correlated to dopamine insufficiency (essential tremor, Huntington’s disease, etc).
Seligiline should not be administered concomitantly with other non-selective MAO-inhibitors. See “Interactions.”
Interactions have been reported between non-selective MAO inhibitors and meperidine (pethidine). Although the mechanism of such interactions has not been completely clarified, patients are advised to avoid the concomitant administration of selegiline with other dopamine enhancing agents, or selective MAO inhibitors and meperidine.
For those who practise sports: The use of this medicine without any therapeutic need may be regarded as doping and produce a positive result in doping tests.
Monotherapy: One quarter (1.25 mg), one half (2.5 mg) to one tablet (5 mg) daily, taken in the morning in one single dose, or divided into two daily doses as necessary.
The most common undesired side effects include: insomnia, dizziness or stupor, headaches, nausea and other gastrointestinal disorders, low blood pressure.
Since Seligiline boosts levodopa action, combined treatment can intensify the typical side effects of this substance as well as the onset of collateral effects linked to the MAO-inhibitor effect, (agitation, insomnia, disorientation, hallucinations, hyperkinesias, nausea, anorexia and other gastroenteric disorders, low blood pressure, dizziness, headaches, asthenia, etc).
Report any side effect not mentioned in this insert to your physician or pharmacist.
DO NOT USE THIS MEDICATION AFTER THE EXPIRY DATE SHOWN ON THE BOX.
Keep out of the reach of children. NOT RECOMMENDED FOR PREGNANT OR LACTACTING WOMEN.
L-deprenyl is what good pharmaceuticals are all about. First it is exceptionally safe, second it protects and enhances mental function, mood and even libido, thirdly, it may even extend life. Imagine a safe agent that enhances both the quality and length of life – I'd certainly encourage others to buy deprenyl over other antiaging therapies.
Many of us here in the States appreciate you making it possible for us to continue to get access to liquid deprenyl.
My wife has benefited greatly from the use of Dep-Pro, her pre-Parkinson shakes are fading fast. She tells me the internal twitching is nearly gone!
I thought to drop you a line and let you know about the benefits of deprenyl for me personally. After three days of 5 mg daily, my essential tremor disappeared. My mind is sharper and suddenly. I can stay up to 10pm instead of going to bed at 8pm every evening. Presently, I feel like a new person. I believe that even my 'senior moments' have disappeared thanks to deprenyl.